Literature DB >> 28545483

Encephalitis associated with human herpesvirus-7 infection in an immunocompetent adult.

Mónica Parra1, Adoración Alcala2, Cristina Amoros2, Anna Baeza2, Antonio Galiana1, David Tarragó3, Miguel Ángel García-Quesada4, Victoria Sánchez-Hellín5.   

Abstract

BACKGROUND: Primary Human herpesvirus-7 (HHV-7) infection usually occurs during childhood and causes several clinical manifestations: mainly exanthem subitum (roseola infantum), followed by a lifelong latent state with possible reactivation in case of immunodeficiency. Nevertheless, some considerably different approaches exist regarding the natural history of HHV-7 and the possible consequences of HHV-7 infection in immunocompetent adults. In particular, little is known about its pathogenic role in central nervous system (CNS) disease in nonimmunosuppressed adults. Specifically, in case of encephalitis, it is important to distinguish between infectious encephalitis and postinfectious encephalomyelitis for the management of patients CASE
PRESENTATION: We describe here a case of encephalitis associated to human herpesvirus-7 with associated polymyeloradiculopathy in an immunocompetent patient which may contribute to the delineation of the approach to a patient profile with a similar clinical presentation and evolution to those presented in the literature.
CONCLUSIONS: This case may alert clinicians to consider this specific etiology in the differential diagnosis of encephalopathy in patients with suspected infectious encephalitis who do not respond to acyclovir or in patients who develop acute polymyeloradiculopathy, considering that HHV-7 may be a pathological factor and that a timely diagnosis is crucial for the early administration of specific treatment.

Entities:  

Keywords:  Clinical significance HHV-7 CNS infection; Human herpesvirus-7 encephalitis; Immunocompetent adults

Mesh:

Year:  2017        PMID: 28545483      PMCID: PMC5445330          DOI: 10.1186/s12985-017-0764-y

Source DB:  PubMed          Journal:  Virol J        ISSN: 1743-422X            Impact factor:   4.099


Background

Human herpesvirus-7 (HHV-7) is a ubiquitous virus that belongs to the subfamily of β-herpesviruses (together with cytomegalovirus and human herpesvirus-6). Primary HHV-7 infection usually occurs during childhood and may cause several clinical manifestations: mainly exanthem subitum (roseola infantum), followed by a lifelong latent state with possible reactivation in case of immunodeficiency [1]. Nevertheless, some considerably different approaches exist regarding the natural history of this infectious agent and the possible consequences of HHV-7 infection in immunocompetent adults, pertaining both to late primary HHV-7 infection or reactivation of the virus from macrophages and/or CD4+ T cells. In particular, little is known about its pathogenic role in central nervous system (CNS) disease in nonimmunosuppressed adults. Specifically, in case of encephalitis, it is important to distinguish between infectious encephalitis and postinfectious encephalomyelitis for the management of patients. We describe here a case of HHV-7 encephalitis with associated polymyeloradiculopathy in an immunocompetent patient.

Case presentation

A 26-year-old immunocompetent male presented with dizziness, blurred vision, a 3-day history of fever, frontal headache, cervical and lumbar pain, and vomiting during the last 24 h. There was no significant personal history apart from animal exposure: contact with dogs and cats several days before the onset of symptoms and the presence of a tick on his back (information provided by his relatives). Physical examination revealed the presence of somnolence. On admission, the patient presented cranial nerve affectation (ophthalmoplegia), vertical nystagmus in attempted supra-version, mitigated osteotendinous reflexes, indifferent bilateral superficial cutaneous reflexes, and dysmetria, which was observed on the finger-to-nose test. A cerebrospinal fluid (CFS) sample contained 110 leucocytes/μl (lymphocytes + monocytes) and 100 red blood cells/μl, 82 mg/dl of protein, and 60 mg/dl of glucose (blood glucose, 108 mg/dl). A second CFS sample obtained 3 days after the collection of the first one contained 200 leucocytes/μl (95% monocytes), 61 mg/dl of protein, and 54 mg/dl of glucose (blood glucose, 88 mg/dl). Progressive deterioration of the level of consciousness with a Glasgow Coma Score (GCS) of 8 (V1, O1, M6) led to a requirement for mechanical ventilation. The patient was empirically treated with acyclovir, ceftriaxone, ampicillin, doxycycline, and corticoids. His level of consciousness improved (GCS 11 [O4, V1, M6]), although the ophthalmoplegia persisted. Electroencephalography (EEG) showed irregular slow activity with slow bilateral waves in the temporal and frontal areas, which was consistent with encephalitis. Magnetic resonance imaging (MRI) of the brain was normal. Normal findings were obtained for a wide spectrum of antibodies (anti-Jo-1, anti-Sm, anti-SS-A, anti-SS-B, anti-nRNP, anti-Scl-70, anti-c-ANCA, anti-p-ANCA, anti-dsDNA, anti-amphiphysin, anti-CV2, anti-PNMA2, anti-Yo (PCCA-1), anti-Hu (ANNA-1), anti-RI (ANNA-2), and anti-ganglioside). On the 5th evolution day, he developed flaccid paralysis of his right arm and lower limbs with abolishment of osteotendinous reflexes. Electromyography (EMG) performed on the 8th evolution day revealed an F-wave alteration in the upper and lower limbs that was indicative of the initial stage of polyradiculoneuritis. Cerebrospinal fluid (CFS), serum, and whole-blood samples were screened for the identification of possible etiologies. Follow-up MRI investigations performed in our patient revealed the presence of cervical and dorsolumbar myelitis. Intravenous immunoglobulins were administered to the patient, who was considered as having acute polymyeloradiculopathy. After treatment, the ophthalmoplegia disappeared, the strength of the upper-right limb was recovered, and the strength of the lower limbs was improved. The patient was subsequently discharged; however, urinary incontinence persisted. Four months later, the patient had recovered completely. The results of the microbiological assessment, according to clinical and risk factors were as follows. First-line investigation: on day 1; gram stain and bacterial culture, alpha-herpesvirus (herpes simplex virus 1, herpes simplex virus 2, and varicella-zoster virus), and enterovirus were negative. On day 3; Treponema pallidum and Cryptococcal neoformans (serum and CFS), Mycoplasma pneumoniae, Epstein–Barr virus, and Cytomegalovirus were negative. Because of animal exposure and insect contact, Borrelia burgdorferi, Borrelia spp., Rickettsia spp., Bartonella, Coxiella burnetii, Anaplasma/Ehrlichia, Brucella, and Toxoplasma (serum and CFS) tests were performed and were negative. Screening for HIV (serology and RNA), hepatitis A, B, and C, and Mycobacterium tuberculosis (CSF) was also negative. Second-line investigation: on day 4; West Nile, Toscana, Choriomeningitis, Yellow fever, Dengue, and Chikungunya arbovirus were negative. Third-line investigation: on day 10, because of the deterioration of the patient and the lack of an etiologic cause for the symptoms, alpha-herpesvirus and enterovirus were screened again, with negative results. In addition, as vector-borne disease was the most likely explanation for the patient’s disease, on day 14 (early convalescent phase) he was tested for Borrelia burgdorferi, Rickettsia conorii, and Coxiella burnetii (serum and whole blood), as well as Rickettsia spp., Bartonella, Coxiella burnetii, and Anaplasma/Ehrlichia (whole blood; frozen on day 7 [acute phase]) in parallel, with negative results. Finally, human herpesvirus-6, HHV-7, and human herpesvirus-8 were suspected in the absence of positive outcomes and presence of deterioration despite treatment with acyclovir. HHV-7 DNA was detected in the first CSF sample by Multiplex Nested PCR, which detects DNA from HHV-6, HHV-7, and HHV-8 on day 18 [2]. Fluorescent anti-HHV-7 IgG testing in serum samples on day 3 and days 14 and 21 revealed an increase in anti-HHV-7 titers from 1:32 to 1:64, in a retrospective analysis. However, HHV-7 antibody avidity testing, to determine primary infection vs reactivation of HHV-7 in the nervous system, could not be performed. Details of the microbiological assessment performed on the patient’s samples are shown in the Additional file 1: Table S1. Acyclovir was discontinued after microbiological diagnosis and the patient was treated with ganciclovir over 3 weeks.

Discussion

Our approach to this patient included a differential diagnosis that excluded noninfectious CNS diseases such as structural lesions, brain abscesses, parameningeal infections, and metabolic and toxic encephalopathies; however, a definitive diagnosis could not be established that discriminated between HHV-7 encephalitis or postinfectious encephalomyelitis. The detection of HHV-7 DNA in the patient’s CSF concomitant with neurological disease in association with the exclusion of all alternative etiological causes (according to the clinical practice guidelines of the Infectious Diseases Society of America [3]) supported HHV-7 as the possible cause of the encephalitis, based on the criteria that were established by Schwartz et al. [4]. As a consequence of antibody avidity could not be determined in our laboratory to differentiate between primary and past infection, we can not certainly establish whether encephalitis associated to HHV-7 infection in our patient was secondary to late primary infection or reactivation. Conversely, HHV-7 is a virus that is highly prevalent and has been detected in normal brain tissue [5]. Therefore, CSF PCR has a low positive predictive value. In fact, the patient had already improved before ganciclovir therapy was administered. Thus, a combination of HHV-7 primoinfection or reactivation and immune response is believed to have contributed to the development of encephalomyelitis. It is likely that HHV-7 was the infecting microorganism that was responsible for the immunological response, taking into account our patient’s clinical improvement after treatment with intravenous immunoglobulin therapy. The case presented here contributes to the delineation of the approach to a patient profile with a similar clinical presentation and evolution to those presented in the literature [6-11]. All relevant information about these cases is presented in Table 1. In our case, despite the administration of empirical antiviral therapy with acyclovir as the first line for viral encephalitis, the patient developed polymyeloradiculopathy consisting of urinary retention, respiratory failure, and flaccid paralysis of the limbs, progressing to quadriplegia. Notably, these findings are similar to those of the HHV-7 encephalitis cases published previously, which occurred in both immunocompetent and nonimmunocompetent adults; this may alert clinicians to consider this specific etiology.
Table 1

Clinical features, diagnosis, and treatment of similar cases reported in the literature

Clinical diagnosis/Immune statusAgeGenderPresentationEvolution before treatmentMicrobiological HHV-7 diagnosisCSFPrimoinfection vs reactivationSpecific TreatmentReference
Encephalitis and flaccid paralysis/Immunocompetent19MaleSevere headache, vomiting, dizziness, and urinary retentionAtaxia, impaired pupillary reflexes, reduced level of consciousness, and flaccid paralysis of the lower limbs progressing to quadriparesisHHV-7 DNA in CSF (PCR [12]) and low avidity HHV-7 IgG65 leucocytes/μl (63 lymphocytes + 2 neutrophils) and 2 red blood cells/μl, elevated protein of 80 mg/dl, and 48,6 mg/dl of glucose (blood glucose 90 mg/dl)P-Ward KN 2002 [6]
Acute myeloradiculopathy/Immunocompetent26MaleProgressive motor weakness, tingling in the extremities, and dysphasiaCranial nerve involvement and autonomic dysfunctionsHHV-7 DNA in CSF by real time-PCR and increase in anti-HHV-7 titers from 1:16 to 1:64 (IFA)Normal at admission with an increase in protein of 89 mg/dl and a modest pleocytosis (8 cells/μl) by day 20.RIntravenous immunoglobulin (400 mg/kg/day) for 5 daysMihara T 2005 [8]
Encephaloradiculomyelitis associated to HHV-7and CMV co-infection/Immunocompetent51MaleFever and gradual loss of strength in lower limbsDisorientation and confusion, flaccid paraplegia, urinary retention, and constipationHHV-7 DNA in CSF (nested PCR)a and anti-HHV-7 IgG but not IgM in serum (IFA)Pleocytosis (250 cells/μl) with 93% lymphocytes, 10 red blood cells/μl, high protein levels (950 mg/dl) and normal glucose.RGanciclovir and dexamethasoneGinanneschi F 2007 [9]
Acute myelitis/Immunocompetent34MaleFever, urinary retention, and weakness in the lower limbs-HHV-7 RNA in CSF (PCR-Microarray, Entherpex®, Genomica)35 leucocytes/μl (predominantly monocytes) elevated protein of 75 mg/dl.-Methylprednisolone (1 g/day) and ganciclovirMiranda M 2011 [10]
Neurological disorder/Immunocompetent27MalePersistent headache and fever-HHV-7 RNA in CSF (PCR-Microarray, Entherpex®, Genomica)160 leucocytes/μl (predominantly monocytes) elevated protein of 75 mg/dl--Miranda M 2011 [10]
Encephalitis with polymyeloradiculopathy/Immunocompetent26MaleHeadache and fever, dizziness, blurred vision, cervical and lumbar pain, and somnolenceFlaccid paralysis of right arm and lower limbs appeared on 5th evolution dayHHV-7 DNA in CSF (Multiplex Nested PCR)110 leucocytes/μl (lymphocytes + monocytes) and 100 red blood cells/μl, elevated protein of 82 mg/dl, and 60 mg/dl of glucose (blood glucose, 108 mg/dl)P or R or PEIntravenous immunoglobulin GanciclovirCurrent case
Acute myelitis/Bone marrow recipient47MalePyrexia and urinary retentionSpastic paraparesisHHV-7 DNA in CSF (PCR [12]) and high avidity HHV-7 IgG before transplant48 leucocytes/μl (predominantly lymphocytes), 235 red blood cells/μl, elevated protein of 1.22 g/l, and 52.2 mg/dl of glucose (blood glucose mg/dl 99)RMethylprednisolone (1 g/day)Ward KN 2002 [7]
Acute myelitis/HIV-infected40MaleAsymmetric paresthesia and hypoesthesia in lower limbsFlaccid paraparesis and severe lower-limb hypoesthesiaHHV-7 DNA in CSF (PCR-Microarray, Clart® Entherpex, Genomica)1 lymphocyte, 0 erythrocytes, 25,88 mg/dl proteins and 59 mg/dl glucoseP or RFoscarnetEscobar-Villalba A 2016 [11]

aNested PCR performed on CSF sample was also positive for cytomegalovirus (CMV); IFA, indirect immunofluorescence assay; P: Primoinfection; R: Reactivation; PE: Postinfectious encephalomyelitis

Clinical features, diagnosis, and treatment of similar cases reported in the literature aNested PCR performed on CSF sample was also positive for cytomegalovirus (CMV); IFA, indirect immunofluorescence assay; P: Primoinfection; R: Reactivation; PE: Postinfectious encephalomyelitis

Conclusions

It may be concluded, regarding the importance of the confirmed laboratory diagnosis, that HHV-7 should be considered in the differential diagnosis of encephalopathy in patients with suspected infectious encephalitis who do not respond to acyclovir or in patients who develop acute polymyeloradiculopathy, considering that HHV-7 may be a pathological factor and that a timely diagnosis is crucial for the early administration of specific treatment.
  12 in total

Review 1.  Acute myelitis by human herpes virus 7 in an HIV-infected patient.

Authors:  Alfonso Escobar-Villalba; Susana Sainz de la Maza; Paula Pérez Torre; Juan Carlos Galán; Mario Rodríguez-Domínguez; Enric Monreal Laguillo; Pedro Luis Martínez Ulloa; Javier Buisán Catevilla; Iñigo Corral
Journal:  J Clin Virol       Date:  2016-02-11       Impact factor: 3.168

2.  [Meningomyelitis associated with infection by human herpes virus 7: report of two cases].

Authors:  Marcelo Miranda C; Juan Pablo Torres T; Carmen Larrañaga L; Guillermo Acuña L
Journal:  Rev Med Chil       Date:  2012-03-07       Impact factor: 0.553

3.  Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient.

Authors:  K N Ward; R P White; S Mackinnon; M Hanna
Journal:  Bone Marrow Transplant       Date:  2002-12       Impact factor: 5.483

4.  Prevalence and distribution of human herpesvirus 7 in normal brain.

Authors:  P K Chan; H K Ng; J L Cheung; K C Ng; A F Cheng
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

5.  Postinfectious myeloradiculoneuropathy with cranial nerve involvements associated with human herpesvirus 7 infection.

Authors:  Takateru Mihara; Tatsuro Mutoh; Tetsusi Yoshikawa; Shigeaki Yano; Yoshizo Asano; Hiroko Yamamoto
Journal:  Arch Neurol       Date:  2005-11

6.  Encephaloradiculomyelitis associated to HHV-7 and CMV co-infection in immunocompetent host.

Authors:  Federica Ginanneschi; Donatella Donati; Donatella Moschettini; Federica Dominici; Claudio Cermelli; Alessandro Rossi
Journal:  Clin Neurol Neurosurg       Date:  2006-05-19       Impact factor: 1.876

7.  A multiplex PCR assay for the simultaneous detection of human herpesvirus 6 and human herpesvirus 7, with typing of HHV-6 by enzyme cleavage of PCR products.

Authors:  I M Kidd; D A Clark; J A Bremner; D Pillay; P D Griffiths; V C Emery
Journal:  J Virol Methods       Date:  1998-01       Impact factor: 2.014

8.  Delayed primary HHV-7 infection and neurologic disease.

Authors:  Kevin L Schwartz; Susan E Richardson; Katherine N Ward; Callum Donaldson; Daune MacGregor; Brenda Banwell; Sanjay Mahant; Ari Bitnun
Journal:  Pediatrics       Date:  2014-05-12       Impact factor: 7.124

Review 9.  Molecular biology and clinical associations of Roseoloviruses human herpesvirus 6 and human herpesvirus 7.

Authors:  Elisabetta Caselli; Dario Di Luca
Journal:  New Microbiol       Date:  2007-07       Impact factor: 2.479

10.  Neuroinvasion during delayed primary HHV-7 infection in an immunocompetent adult with encephalitis and flaccid paralysis.

Authors:  K N Ward; P Kalima; K M MacLeod; T Riordan
Journal:  J Med Virol       Date:  2002-08       Impact factor: 2.327

View more
  7 in total

1.  Molecular detection of human herpesvirus 7 DNA in cerebrospinal fluid from adult patients with neurological disorders.

Authors:  Íñigo Corral; Susana Sainz de la Maza; Mario Rodríguez; Michal-Maciej Kawiorski; María-José López-Martínez; Juan-Carlos Galán
Journal:  J Neurovirol       Date:  2018-03-13       Impact factor: 2.643

2.  Herpesvirus and neurological manifestations in patients with severe coronavirus disease.

Authors:  Vanessa Cristine de Souza Carneiro; Soniza Vieira Alves-Leon; Dmitry José de Santana Sarmento; Wagner Luis da Costa Nunes Pimentel Coelho; Otacilio da Cruz Moreira; Andreza Lemos Salvio; Carlos Henrique Ferreira Ramos; Carlos Henrique Ferreira Ramos Filho; Carla Augusta Barreto Marques; João Paulo da Costa Gonçalves; Luciane Almeida Amado Leon; Vanessa Salete de Paula
Journal:  Virol J       Date:  2022-06-08       Impact factor: 5.913

3.  Persistent Roseoloviruses Infection in Adult Patients with Epilepsy.

Authors:  Santa Rasa-Dzelzkaleja; Sabine Gravelsina; Svetlana Chapenko; Zaiga-Nora Krukle; Simons Svirskis; Normunds Suna; Elena Kashuba; Guntis Karelis; Modra Murovska
Journal:  Brain Sci       Date:  2020-05-11

4.  Enhanced Virus Detection and Metagenomic Sequencing in Patients with Meningitis and Encephalitis.

Authors:  Anne Piantadosi; Shibani S Mukerji; Simon Ye; Tracey A Cho; Pardis Sabeti; Michael J Leone; Lisa M Freimark; Daniel Park; Gordon Adams; Jacob Lemieux; Sanjat Kanjilal; Isaac H Solomon; Asim A Ahmed; Robert Goldstein; Vijay Ganesh; Bridget Ostrem; Kaelyn C Cummins; Jesse M Thon; Cormac M Kinsella; Eric Rosenberg; Matthew P Frosch; Marcia B Goldberg
Journal:  mBio       Date:  2021-08-31       Impact factor: 7.867

5.  Case Report: Overlapping Syndrome of Anti-NMDAR Encephalitis and MOG Inflammatory Demyelinating Disease in a Patient With Human Herpesviruses 7 Infection.

Authors:  Sisi Li; Minjin Wang; Hancong Li; Jierui Wang; Qi Zhang; Dong Zhou; Jinmei Li
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

6.  Development of an enzyme-linked immunosorbent assay for diagnosis of human herpesvirus-7 infection.

Authors:  Ana Lia Pradella Puglia; Murilo de Freitas Peigo; Fernando Russo Costa Bomfim; Ronaldo Luis Thomasini
Journal:  Rev Soc Bras Med Trop       Date:  2020-03-16       Impact factor: 1.581

Review 7.  Extracellular vesicles: novel vehicles in herpesvirus infection.

Authors:  Lingzhi Liu; Quan Zhou; Yan Xie; Lielian Zuo; Fanxiu Zhu; Jianhong Lu
Journal:  Virol Sin       Date:  2017-10-30       Impact factor: 4.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.